Lamictal and Erythema multiforme - a phase IV clinical study of FDA data

Summary:

Erythema multiforme is found among people who take Lamictal, especially for people who are female, 30-39 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Lamictal and have Erythema multiforme. It is created by eHealthMe based on reports of 69,354 people who have side effects when taking Lamictal from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Aug, 06, 2023

69,354 people reported to have side effects when taking Lamictal.
Among them, 2,497 people (3.6%) have Erythema multiforme.

What is Lamictal?

Lamictal has active ingredients of lamotrigine. It is often used in bipolar disorder. eHealthMe is studying from 77,574 Lamictal users for its effectiveness, alternative drugs and more.

What is Erythema multiforme?

Erythema multiforme (a type of hypersensitivity reaction) is found to be associated with 2,949 drugs and 2,835 conditions by eHealthMe.

Number of Lamictal and Erythema multiforme reports submitted per year:

Could Lamictal cause Erythema multiforme?

* Approximation only. Some reports may have incomplete information.

Do you take Lamictal and have Erythema multiforme?

Check whether Erythema multiforme is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Alonso-Navarro H, Montes JM, Plaza-Nieto JF, Jiménez-Jiménez FJ, "Cataplexy Possibly Associated With Lamotrigine", Journal of clinical psychopharmacology, 2016 Aug .
Gupta MC, Khanna J, Mathur R, Mittal N, "Lamotrigine-induced fulminant hepatic failure: an unusual presentation", IMSEAR, 2015 Jan .
Tognetti L, Giorgini S, Lotti T, "Erythema multiforme-like eruption from a slimming drug preparation cutaneous adverse drug reaction", Indian dermatology online journal, 2011 Jan .

Related studies

How severe was Erythema multiforme and when was it recovered:

Erythema multiforme in Lamictal

Expand to all the drugs that have ingredients of lamotrigine:

Erythema multiforme and drugs with ingredients of lamotrigine (4,210 reports)

Alternative drugs to, pros and cons of Lamictal:

Lamictal (77,574 reports)

Common Lamictal side effects:

Rashes (redness): 7,619 reports
Drug ineffective: 4,554 reports
Fever: 3,676 reports
Dizziness: 3,666 reports
Fatigue (feeling of tiredness): 3,650 reports
Headache (pain in head): 3,582 reports
Stress and anxiety: 3,398 reports

Browse all side effects of Lamictal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Erythema multiforme treatments and more:

Erythema multiforme (51,191 reports)

COVID vaccines that are related to Erythema multiforme:

Common drugs associated with Erythema multiforme:

All the drugs that are associated with Erythema multiforme:

Erythema multiforme (2,949 drugs)

Common conditions associated with Erythema multiforme:

High blood pressure: 2,546 reports
Epilepsy: 1,791 reports
Fever: 1,545 reports
Pain: 1,525 reports
Depression: 1,255 reports

All the conditions that are associated with Erythema multiforme:

Erythema multiforme (2,835 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lamotrigine (the active ingredients of Lamictal) and Lamictal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.